Imaging biomarkers in drug development: Case studies

Translational Medicine and Drug Discovery

Volumn , Issue , 2011, Pages 222-264

  Tauscher, Johannes T ^a   Schwarz, Adam J ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882585066     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511976087.010     Document Type: Chapter

References (246)

1. Adams CP, & Brantner VV. (2006). Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff. (Millwood). 25(2), 420–428.
2. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. (2004). Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann. Neurol. 55(3), 306–319.
3. Farde L, Hall H, Ehrin E, & Sedvall G. (1986). Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science. 231(4735), 258–261.
4. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, & Dursun SM. (2008). Glutamate and the neural basis of the subjective effects of ketamine: A pharmacomagnetic resonance imaging study. Arch. Gen. Psychiatry. 65(2), 154–164.
5. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, et al. (2009). Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur. Neuropsychopharmacol. 20, 80–87.
6. Galbraith SM. (2006).MR in oncology drug development. NMR Biomed. 19(6), 681–689.
7. Steiger P. (2009).Use of imaging biomarkers for regulatory studies. J. Bone Joint Surg. 91(Suppl 1), 132–136.
8. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228–247.
9. Olson S, Robinson S, & Giffin R. (2009). Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press.
10. Woodcock J, &Woosley R. (2008). The FDA critical path initiative and its influence on new drug development. Ann. Rev.Med. 59, 1–12.
11. Kapur S, Remington G, Jones C, Wilson A, DaSilva J, Houle S, et al. (1996). High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. Am. J. Psychiatry. 153(7), 948–950.
12. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, & Sedvall G. (1992). Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49(7), 538– 544.
13. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, & Welch MJ. (1984). A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 15(3), 217–227.
14. Kapur S, Zipursky R, Jones C, Remington G, & Houle S. (2000). Relationship between dopamine D(2) occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157(4), 514–520.
15. Tauscher J, & Kapur S. (2001). Choosing the right dose of antipsychotics in schizophrenia: Lessons from neuroimaging studies. CNS Drugs. 15(9), 671– 678.
16. Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, et al. (1997). Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology. 17(3), 175–185.
17. Tauscher J, Jones C, Remington G, Zipursky RB, & Kapur S. (2002). Significant dissociation of brain and plasma kinetics with antipsychotics. Mol. Psychiatry. 7(3), 317–321.
18. Tauscher J, Pirker W, de Zwaan M, Asenbaum S, Brucke T, & Kasper S. (1999). In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur. Neuropsychopharmacol. 9(1–2), 177–179.
19. Meyer JH. (2007). Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J. Psychiatry Neurosci. 32(2), 86–102.
20. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. (2001). Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. Am. J. Psychiatry. 158(11), 1843–1849.
21. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am. J. Psychiatry. 161(5), 826–835.
22. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, et al. (2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch. Gen. Psychiatry. 60(4), 386–391.
23. Raichle ME. (1998). Imaging themind. Semin. Nucl.Med. 28(4), 278–289.
24. Raichle ME. (2009). A brief history of human brain mapping. Trends Neurosci. 32(2), 118–126.
25. Ogawa S, Lee TM, Kay AR, & Tank DW. (1990). Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc. Natl. Acad. Sci. U. S. A. 87(24), 9868–9872.
26. Bandettini PA, Wong EC, Hinks RS, Tikofsky RS, & Hyde JS. (1992). Time course EPI of human brain function during task activation. Magn. Reson. Med. 25(2), 390–397.
27. Blamire AM, Ogawa S, Ugurbil K, Rothman D, McCarthy G, Ellermann JM, et al. (1992). Dynamic mapping of the human visual cortex by high-speed magnetic resonance imaging. Proc. Natl. Acad. Sci. U. S. A. 89(22), 11069–11073.
28. Frahm J, Bruhn H, Merboldt KD, & Hanicke W. (1992). Dynamic MR imaging of human brain oxygenation during rest and photic stimulation. J. Magn. Reson. Imaging. 2(5), 501–505.
29. Kwong KK, Belliveau JW, Chesler DA, Goldberg IE, Weisskoff RM, Poncelet BP, et al. (1992). Dynamic magnetic resonance imaging of human brain activity during primary sensory stimulation. Proc. Natl. Acad. Sci.U. S. A. 89(12), 5675– 5679.
30. Honey G, & Bullmore E. (2004). Human pharmacological MRI. Trends. Pharmacol. Sci. 25(7), 366–374.
31. Schweinhardt P, Bountra C, & Tracey I. (2006). Pharmacological fMRI in the development of new analgesic compounds. NMR Biomed. 19(6), 702– 711.
32. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, et al. (2003). Ketamine alters neural processing of facial emotion recognition in healthymen: An fMRI study. Neuroreport. 14(3), 387–391.
33. Anderson IM, Del-Ben CM, McKie S, Richardson P, Williams SR, Elliott R, et al. (2007). Citalopram modulation of neuronal responses to aversive face emotions: A functional MRI study. Neuroreport. 18(13), 1351–1355.
34. Anderson IM, McKie S, Elliott R, Williams SR, & Deakin JF. (2008). Assessing human 5-HT function in vivo with pharmaco MRI. Neuropharmacol. 55(6), 1029–1037.
35. Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, et al. (2007). Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacol. 32(5), 1011–1020.
36. Becerra L, Harter K, Gonzalez RG, & Borsook D. (2006). Functional magnetic resonance imaging measures of the effects of morphine on central nervous system circuitry in opioid-naive healthy volunteers. Anesth. Analg. 103(1), 208– 216.
37. Borsook D, Becerra L, & Hargreaves R. (2006). A role for fMRI in optimizing CNS drug development. Nat. Rev. Drug Discov. 5(5), 411–424.
38. Fu CH, Williams SC, Brammer MJ, Suckling J, Kim J, Cleare AJ, et al. (2007). Neural responses to happy facial expressions in major depression following antidepressant treatment. Am. J. Psychiatry. 164(4), 599–607.
39. Fu CH, Williams SC, Cleare AJ, Brammer MJ, Walsh ND, Kim J, et al. (2004). Attenuation of the neural response to sad faces in major depression by antidepressant treatment: A prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry. 61(9), 877–889.
40. Goekoop R, Barkhof F, Duschek EJ, Netelenbos C, Knol DL, Scheltens P, et al. (2006). Raloxifene treatment enhances brain activation during recognition of familiar items: A pharmacological fMRI study in healthy elderly males. Neuropsychopharmacol. 31(7), 1508–1518.
41. Honey GD, Suckling J, Zelaya F, Long C, Routledge C, Jackson S, et al. (2003). Dopaminergic drug effects on physiological connectivity in a human corticostriato- thalamic system. Brain. 126(Pt 8), 1767–1781.
42. Honey RA, Honey GD, O’Loughlin C, Sharar SR, Kumaran D, Bullmore E., et al. (2004). Acute ketamine administration alters the brain responses to executive demands in a verbal workingmemory task: An fMRI study. Neuropsychopharmacol. 29(6), 1203–1214.
43. Lorenz IH, Egger K, Schubert H, Schnurer C, Tiefenthaler W, Hohlrieder M, et al. (2008). Lornoxicam characteristically modulates cerebral painprocessing in human volunteers: A functional magnetic resonance imaging study. Br. J. Anaesth. 100(6), 827–833.
44. Sheline YI, Barch DM, Donnelly JM, Ollinger JM, Snyder AZ, & Mintun MA. (2001). Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: An fMRI study. Biol. Psychiatry. 50(9), 651–658.
45. Stein EA, Pankiewicz J, Harsch HH, Cho JK, Fuller SA, Hoffmann RG, et al. (1998).Nicotine-induced limbic cortical activation in the human brain: A functional MRI study. Am. J. Psychiatry. 155(8), 1009–1015.
46. Thiel CM, Henson RN, & Dolan RJ. (2002). Scopolamine but not lorazepam modulates face repetition priming: A psychopharmacological fMRI study. Neuropsychopharmacol. 27(2), 282–292.
47. Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, et al. (2002). Combining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanil. Neuroimage. 16(4), 999–1014.
48. Borsook D, Bleakman D, Hargreaves R, Upadhyay J, Schmidt KF, & Becerra L. (2008). A ‘BOLD’ experiment in defining the utility of fMRI in drug development. Neuroimage. 42(2), 461–466.
49. Logothetis NK. (2008). What we can do and what we cannot do with fMRI. Nature. 453(7197), 869–878.
50. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, et al. (1997). Acute effects of cocaine on human brain activity and emotion. Neuron. 19(3), 591–611.
51. Kufahl PR, Li Z, Risinger RC, Rainey CJ, Wu G, Bloom AS, et al. (2005). Neural responses to acute cocaine administration in the human brain detected by fMRI. Neuroimage. 28(4), 904–914.
52. Kufahl P, Li Z, Risinger R, Rainey C, Piacentine L, Wu G, et al. (2008). Expectation modulates human brain responses to acute cocaine: A functional magnetic resonance imaging study. Biol. Psychiatry. 63(2), 222–230.
53. Leppa M, Korvenoja A, Carlson S, Timonen P, Martinkauppi S, Ahonen J, et al. (2006). Acute opioid effects on human brain as revealed by functional magnetic resonance imaging. Neuroimage. 31(2), 661–669.
54. Chen YI, Choi JK, & Jenkins BG. (2005). Mapping interactions between dopamine and adenosine A2a receptors using pharmacologic MRI. Synapse. 55(2), 80–88.
55. Chen YC, Galpern WR, Brownell AL, Matthews RT, Bogdanov M, Isacson O, et al. (1997). Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: Correlation with PET, microdialysis, and behavioral data. Magn. Reson.Med. 38(3), 389–398.
56. Chen YC, Choi JK, Andersen SL, Rosen BR, & Jenkins BG. (2005). Mapping dopamine D2/D3 receptor function using pharmacological magnetic resonance imaging. Psychopharmacol. (Berl). 180(4), 705–715.
57. Reese T, Bjelke B, Porszasz R, Baumann D, Bochelen D, Sauter A, et al. (2000). Regional brain activation by bicuculline visualized by functional magnetic resonance imaging. Time-resolved assessment of bicuculline-induced changes in local cerebral blood volume using an intravascular contrast agent. NMR Biomed. 13(1), 43–49.
58. Schwarz A, Gozzi A, Reese T, Bertani S, Crestan V, Hagan J, et al. (2004). Selective dopamine D(3) receptor antagonist SB-277011—A potentiates phMRI response to acute amphetamine challenge in the rat brain. Synapse. 54(1), 1– 10.
59. Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, & Bifone A. (2006). Regionspecific effects of nicotine on brain activity: A pharmacological MRI study in the drug-naive rat. Neuropsychopharmacol. 31(8), 1690–1703.
60. Gozzi A, Large CH, Schwarz A, Bertani S, Crestan V, & Bifone A. (2008). Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacol. 33(7), 1690– 1703.
61. Ireland MD, Lowe AS, Reavill C, James MF, Leslie RA, & Williams SC. (2005). Mapping the effects of the selective dopamine D2/D3 receptor agonist quinelorane using pharmacological magnetic resonance imaging. Neuroscience. 133(1), 315–326.
62. Skoubis PD, Hradil V, Chin CL, Luo Y, Fox GB, & McGaraughty S. (2006). Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats. Neuroscience. 137(2), 583–591.
63. Xu H, Li SJ, Bodurka J, Zhao X, Xi ZX, & Stein EA. (2000). Heroin-induced neuronal activation in rat brain assessed by functional MRI. Neuroreport. 11(5), 1085–1092.
64. Detre JA, & Wang J. (2002). Technical aspects and utility of fMRI using BOLD and ASL. Clin. Neurophysiol. 113(5), 621–634.
65. Williams DS. (2006). Quantitative perfusion imaging using arterial spin labeling. MethodsMol.Med. 124, 151–73.
66. O’Gorman RL, Mehta MA, Asherson P, Zelaya FO, Brookes KJ, Toone BK, et al. (2008). Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: A non-invasive MRI pilot study. Neuroimage. 42(1), 36–41.
67. Jenkins BG, Sanchez-Pernaute R, Brownell AL, Chen YC, & Isacson O. (2004). Mapping dopamine function in primates using pharmacologicmagnetic resonance imaging. J. Neurosci. 24(43), 9553–9560.
68. Andersen AH, Zhang Z, Barber T, Rayens WS, Zhang J, Grondin R, et al. (2002). Functional MRI studies in awake rhesusmonkeys:Methodological and analytical strategies. J. Neurosci.Methods. 118(2), 141–152.
69. Bingel U, Quante M, Knab R, Bromm B, Weiller C, & Buchel C. (2003). Single trial fMRI reveals significant contralateral bias in responses to laser painwithin thalamus and somatosensory cortices. Neuroimage. 18(3), 740–748.
70. Borras MC, Becerra L, Ploghaus A, Gostic JM, DaSilva A, Gonzalez RG, et al. (2004). fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. J. Neurophysiol. 91(6), 2723–2733.
71. Wise RG, Williams P, & Tracey I. (2004).Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. Neuropsychopharmacol. 29(3), 626–635.
72. Borsook D, & Becerra L. (2006). Breaking down the barriers: fMRI applications in pain, analgesia and analgesics. Mol. Pain. 2, 30.
73. Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, et al. (2008).Differential opioid action on sensory and affective cerebral pain processing. Clin. Pharmacol. Ther. 83(4), 577–588.
74. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, et al. (2005). Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. Proc. Natl. Acad. Sci. U. S. A. 102(50), 18195–18200.
75. Nahas Z, George MS, Horner MD, Markowitz JS, Li X, Lorberbaum JP, et al. (2003). Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: A pilot double-blind placebo controlled BOLD fMRI study. Neurocase. 9(3), 274–282.
76. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, et al. (2005). The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: An FMRI study. Neuropsychopharmacol. 30(9), 1724–1734.
77. Muller U, Suckling J, Zelaya F, Honey G, Faessel H, Williams SC, et al. (2005). Plasma level-dependent effects of methylphenidate on task-related functional magnetic resonance imaging signal changes. Psychopharmacology (Berl). 180(4), 624–633.
78. Yahata N, Takahashi H, & Okubo Y. (2005). Pharmacological modulations in human cognitive processes: An fMRI study. J. NipponMed. Sch. 72(1), 2–3.
79. Biswal B, Yetkin FZ, Haughton VM, & Hyde JS. (1995). Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn. Reson.Med. 34(4), 537–541.
80. Fox MD, Snyder AZ, Vincent JL, Corbetta M, Van Essen DC, & Raichle ME. (2005). The human brain is intrinsically organized into dynamic, anticorrelated functional networks. Proc. Natl. Acad. Sci. U. S. A. 102(27), 9673–9678.
81. Shehzad Z, Kelly AM, Reiss PT, Gee DG, Gotimer K, Uddin LQ, et al. (2009). The resting brain: Unconstrained yet reliable. Cereb. Cortex. 19(10), 2209–2229.
82. Damoiseaux JS, Rombouts SA, Barkhof F, Scheltens P, Stam CJ, Smith SM, et al. (2006). Consistent resting-state networks across healthy subjects. Proc. Natl. Acad. Sci. U. S. A. 103(37), 13848–13853.
83. Achard S, & Bullmore E. (2007). Efficiency and cost of economical brain functional networks. PloS Comput. Biol. 3(2), e17.
84. Anand A, Li Y, Wang Y, Wu J, Gao S, Bukhari L, et al. (2005). Antidepressant effect on connectivity of the mood-regulating circuit: An FMRI study. Neuropsychopharmacol. 30(7), 1334–1344.
85. Kelly C, de Zubicaray G, Di Martino A, Copland DA, Reiss PT, Klein DF, et al. (2009). L-dopamodulates functional connectivity in striatal cognitive and motor networks: A double-blind placebo-controlled study. J. Neurosci. 29(22), 7364–7378.
86. Greicius M. (2008). Resting-state functional connectivity in neuropsychiatric disorders. Curr. Opin. Neurol. 21(4), 424–430.
87. Verma A, Declercq R, Coimbra A, & Achten E. (2009). Incorporating functional MRI into clinical pharmacology trials. In: Imaging in CNS Drug Discovery and Development, edited by Borsook D. Springer, New York.
88. Large CH. (2007). Do NMDA receptor antagonistmodels of schizophrenia predict the clinical efficacy of antipsychotic drugs? J. Psychopharmacol. 21(3), 283–301.
89. Littlewood CL, Cash D, Dixon AL, Dix SL, White CT, O’Neill MJ, et al. (2006). Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage. 32(4), 1733–1746.
90. Littlewood CL, Jones N, O’NeillMJ, Mitchell SN, Tricklebank M, &Williams SC. (2006). Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacol. (Berl). 186(1), 64–81.
91. Gozzi A, Schwarz A, Crestan V, & Bifone A. (2008). Drug-anaesthetic interaction in phMRI: The case of the psychotomimetic agent phencyclidine. Magn. Reson. Imaging. 26(7), 999–1006.
92. Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, et al. (2008). Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacol. (Berl). 201(2), 273–284.
93. Duncan GE, Leipzig JN, Mailman RB, & Lieberman JA. (1998). Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res. 812(1–2), 65–75.
94. Duncan GE, Miyamoto S, Leipzig JN, & Lieberman JA. (2000). Comparison of the effects of clozapine, risperidone, and olanzapine on ketamine-induced alterations in regional brain metabolism. J. Pharmacol. Exp. Ther. 293(1), 8–14.
95. Langsjo JW, Kaisti KK, Aalto S, Hinkka S, Aantaa R, Oikonen V, et al. (2003). Effects of subanesthetic doses of ketamine on regional cerebral blood flow, oxygen consumption, and blood volume in humans. Anesthesiology. 99(3), 614– 623.
96. Langsjo JW, Maksimow A, Salmi E, Kaisti K, Aalto S, Oikonen V, et al. (2005). Sketamine anesthesia increases cerebral blood flow in excess of the metabolic needs in humans. Anesthesiology. 103(2), 258–268.
97. Langsjo JW, Salmi E, Kaisti KK, Aalto S, Hinkka S, Aantaa R, et al. (2004). Effects of subanesthetic ketamine on regional cerebral glucose metabolism in humans. Anesthesiology. 100(5), 1065–1071.
98. Apkarian AV, Bushnell MC, Treede RD, & Zubieta JK. (2005). Human brain mechanisms of pain perception and regulation in health and disease. Eur. J. Pain. 9(4), 463–484.
99. Cole LJ, Farrell MJ, Duff EP, Barber JB, Egan GF, & Gibson SJ. (2006). Pain sensitivity and fMRI pain-related brain activity in Alzheimer’s disease. Brain. 129(Pt 11), 2957–2965.
100. Davis KD, Kwan CL, Crawley AP, & Mikulis DJ. (1998). Event-related fMRI of pain: Entering a new era in imaging pain. Neuroreport. 9(13), 3019–3023.
101. Peyron R, Laurent B, & Garcia-Larrea L. (2000). Functional imaging of brain responses to pain. A review and meta-analysis. Neurophysiol. Clin. 30(5), 263– 288.
102. Owen DG, Bureau Y, Thomas AW, Prato FS, & St. Lawrence KS. (2008).Quantification of pain-induced changes in cerebral blood flow by perfusionMRI. Pain. 136(1–2), 85–96.
103. Geha PY, & Apkarian AV. Brain imaging findings in neuropathic pain. (2005). Curr. Pain Headache Rep. 9(3), 184–188.
104. Moisset X, & Bouhassira D. (2007). Brain imaging of neuropathic pain. Neuroimage. 37(Suppl 1), S80–S88.
105. Meyer-Lindenberg A, & Weinberger DR. (2006). Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat. Rev. Neurosci. 7(10), 818– 827.
106. Meyer-Lindenberg A, & Zink CF. (2007). Imaging genetics for neuropsychiatric disorders. Child Adolesc. Psychiatr. Clin. N. Am. 16(3), 581–597.
107. Hariri AR, Drabant EM, Munoz KE, Kolachana BS, Mattay VS, Egan MF, et al. (2005). A susceptibility gene for affective disorders and the response of the human amygdala. Arch. Gen. Psychiatry. 62(2), 146–152.
108. Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, et al. (2002). Serotonin transporter genetic variation and the response of the human amygdala. Science. 297(5580), 400–403.
109. Hariri AR, & Weinberger DR. (2003). Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav. 2(6), 341– 349.
110. Roiser JP, de Martino B, Tan GC, Kumaran D, Seymour B, Wood NW, et al. (2009). A genetically mediated bias in decision making driven by failure of amygdala control. J. Neurosci. 29(18), 5985–5991.
111. Dannlowski U, Ohrmann P, Bauer J, Kugel H, Baune BT, Hohoff C, et al. (2007). Serotonergic genes modulate amygdala activity in major depression. Genes Brain Behav. 6(7), 672–676.
112. Munafo MR, Brown SM, &Hariri AR. (2008). Serotonin transporter (5-HTTLPR) genotype and amygdala activation: A meta-analysis. Biol. Psychiatry. 63(9), 852–857.
113. Surguladze SA, Elkin A, Ecker C, Kalidindi S, Corsico A, Giampietro V, et al. (2008). Genetic variation in the serotonin transporter modulates neural system-wide response to fearful faces. Genes Brain Behav. 7(5), 543–551.
114. Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, et al. (2006). Impact of complex genetic variation in COMT on human brain function.Mol. Psychiatry. 11(9), 867–877
115. Tan HY, Chen Q, Goldberg TE, Mattay VS, Meyer-Lindenberg A, Weinberger DR, et al. (2007). Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory. J. Neurosci. 27(49), 13393–13401.
116. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, et al. (2001). Effect of COMT Val108/158Met genotype on frontal lobe function and risk for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 98(12), 6917–6922.
117. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. U. S. A. 100(10), 6186–6191.
118. Blasi G, Mattay VS, Bertolino A, Elvevag B, Callicott JH, Das S, et al. (2005). Effect of catechol-O-methyltransferase val158met genotype on attentional control. J. Neurosci. 25(20), 5038–5045.
119. Tan HY, Chen Q, Sust S, Buckholtz JW, Meyers JD, EganMF, et al. (2007). Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc. Natl. Acad. Sci. U. S. A. 104(30), 12536–12541.
120. Buckholtz JW, Sust S, Tan HY, Mattay VS, Straub RE, Meyer-Lindenberg A, et al. (2007). fMRI evidence for functional epistasis between COMT and RGS4. Mol. Psychiatry. 12(10), 893–895
121. Tan HY, Nicodemus KK, Chen Q, Li Z, Brooke JK, Honea R, et al. (2008). Genetic variation in AKT1 is linked to dopamine-associated prefrontal cortical structure and function in humans. J. Clin. Invest. 118(6), 2200–2208.
122. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, et al. (2004). Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am. J. Psychiatry. 161(10), 1798–1805.
123. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, et al. (2005). Beyond hypofrontality: A quantitative meta-analysis of functional neuroimaging studies of workingmemory in schizophrenia. Hum. BrainMapping. 25(1), 60–69.
124. Davidson RJ, Irwin W, Anderle MJ, & Kalin NH. (2003). The neural substrates of affective processing in depressed patients treated with venlafaxine. Am. J. Psychiatry. 160(1), 64–75.
125. Surguladze S, Brammer MJ, Keedwell P, Giampietro V, Young AW, Travis MJ, et al. (2005). A differential pattern of neural response toward sad versus happy facial expressions inmajor depressive disorder. Biol. Psychiatry. 57(3), 201–209.
126. Chen CH, Lennox B, Jacob R, Calder A, Lupson V, Bisbrown-Chippendale R, et al. (2006). Explicit and implicit facial affect recognition in manic and depressed states of bipolar disorder: A functional magnetic resonance imaging study. Biol. Psychiatry. 59(1), 31–39.
127. Ford JM, Roach BJ, Jorgensen KW, Turner JA, Brown GG, Notestine R, et al. (2009). Tuning in to the voices: A multisite fMRI study of auditory hallucinations. Schizophr. Bull. 35(1), 58–66.
128. Potkin SG, & Ford JM. (2009). Widespread cortical dysfunction in schizophrenia: The FBIRN imaging consortium. Schizophr. Bull. 35(1), 15–18.
129. Haller S, & Bartsch AJ. (2009). Pitfalls in fMRI. Eur. Radiol. 19(11), 2689–2706.
130. Iannetti GD, &Wise RG. (2007). BOLD functional MRI in disease and pharmacological studies: Room for improvement? Magn. Reson. Imaging. 25(6), 978– 988.
131. Suckling J, Ohlssen D, Andrew C, Johnson G, Williams SC, Graves M, et al. (2008). Components of variance in a multicentre functional MRI study and implications for calculation of statistical power. Hum. Brain Mapping. 29(10), 1111–1122.
132. Desmond JE, & Glover GH. (2002). Estimating sample size in functional MRI (fMRI) neuroimaging studies: Statistical power analyses. J. Neurosci.Methods. 118(2), 115–128.
133. Mumford JA, & Nichols TE. (2008). Power calculation for group fMRI studies accounting for arbitrary design and temporal autocorrelation. Neuroimage. 39(1), 261–268.
134. Murphy K, & Garavan H. (2005). Deriving the optimal number of events for an event-related fMRI study based on the spatial extent of activation. Neuroimage. 27(4), 771–777.
135. Friedman L, & Glover GH. (2006). Report on a multicenter fMRI quality assurance protocol. J.Magn. Reson. Imaging. 23(6), 827–839.
136. Friedman L, Stern H, Brown GG, Mathalon DH, Turner J, Glover GH, et al. (2008). Test-retest and between-site reliability in a multicenter fMRI study. Hum. BrainMapping. 29(8), 958–972.
137. Miller G. (2009). Alzheimer’s biomarker initiative hits its stride. Science. 326(5951), 386–389.
138. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, et al. (2009). Associations between cognitive, functional, and FDG-PETmeasures of decline in AD and MCI. Neurobiol. Aging. Aug. 4. E-pub ahead of print.
139. Hua X, Lee S, Yanovsky I, Leow AD, Chou YY, Ho AJ, et al. (2009). Optimizing power to track brain degeneration in Alzheimer’s disease and mild cognitive impairment with tensor-based morphometry: An ADNI study of 515 subjects. Neuroimage. 48(4), 668–681.
140. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. (2001). Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer’s disease. J. Neurosci. 21(24), RC189.
141. Verhoeff NP, Wilson AA, Takeshita S, Trop L, Hussey D, Singh K, et al. (2004). In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am. J. Geriatr. Psychiatry. 12(6), 584–595.
142. Choi SR, Golding G, Zhuang Z, Zhang W, Lim N, Hefti F, et al. (2009). Preclinical properties of 18F-AV-45: A PET agent for Abeta plaques in the brain. J. Nucl. Med. 50(11), 1887–1894.
143. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Nagren K, et al. (2009). Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study. Neurology. 73(10), 754–760.
144. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, & Piedbois P. (2000). Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-Analysis Group in Cancer. Lancet. 356(9227), 373–378.
145. El-Maraghi RH, & Eisenhauer EA. (2008). Review of phase II trial designs used in studies ofmolecular targeted agents: Outcomes and predictors of success in phase III. J. Clin. Oncol. 26(8), 1346–1354.
146. Goffin J, Baral S, Tu D, Nomikos D, & Seymour L. (2005). Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin. Cancer Res. 11(16), 5928– 5934.
147. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, et al. (1997). Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the European Lung CancerWorking Party. Eur. J. Cancer. 33(14), 2326–2332.
148. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92(3), 205–216.
149. Workman P, Aboagye EO, Chung YL, Griffiths JR, Hart R, Leach MO, et al. (2006).Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl. Cancer Inst. 98(9), 580–598.
150. Schwarz AJ, Maisey NR, Collins DJ, Cunningham D, Huddart R, & Leach MO. (2002). Early in vivo detection of metabolic response: A pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol. 75(900), 959–966.
151. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, et al. (2004). Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting responsewith in vivo (1)HMR spectroscopy – a pilot study at 4 T. Radiology. 233(2), 424–431.
152. O’Connor JP, Jackson A, Parker GJ, & Jayson GC. (2007). DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br. J. Cancer. 96(2), 189–195.
153. Hamstra DA, Galban CJ, Meyer CR, Johnson TD, Sundgren PC, Tsien C, et al. (2008). Functional diffusionmap as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival. J. Clin. Oncol. 26(20), 3387–3394.
154. Padhani AR, & Leach MO. (2005). Antivascular cancer treatments: Functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom. Imaging. 30(3), 324–341.
155. Wahl RL, Jacene H, Kasamon Y, & Lodge MA. (2009). FromRECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J.Nucl.Med. 50(Suppl 1), 122S–150S.
156. Hayes C, Padhani AR, & Leach MO. (2002). Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 15(2), 154–163.
157. Padhani AR. (2003). MRI for assessing antivascular cancer treatments. Br. J. Radiol. 76 Spec No 1, S60–S80.
158. Miller JC, Pien HH, Sahani D, Sorensen AG, & Thrall JH. (2005). Imaging angiogenesis: Applications and potential for drug development. J. Natl. Cancer Inst. 97(3), 172–187.
159. Folkman J. (1971). Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285(21), 1182–1186.
160. Folkman J. (1985). Tumor angiogenesis. Adv. Cancer Res. 43, 175–203.
161. Kerbel RS. (2008). Tumor angiogenesis. N. Engl. J.Med. 358(19), 2039–2049.
162. Jackson A, Buckley DL, & Parker GJ. (eds.). (2005). Dynamic Contrast- EnhancedMagnetic Resonance Imaging in Oncology. Berlin: Springer-Verlag.
163. Tofts PS. (1997). Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J.Magn. Reson. Imaging. 7(1), 91–101.
164. Taylor JS, Tofts PS, Port R, Evelhoch J., Knopp M, Reddick WE, et al. (1999).MR imaging of tumor microcirculation: Promise for the new millennium. J. Magn. Reson. Imaging. 10(6), 903–907.
165. Tofts PS, Brix G, Buckley DL, Evelhoch J., Henderson E, Knopp MV, et al. (1999). Estimating kinetic parameters from dynamic contrast-enhanced T(1)- weighted MRI of a diffusible tracer: Standardized quantities and symbols. J.Magn. Reson. Imaging. 10(3), 223–232.
166. Parker GJ, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE, et al. (1997). Probing tumormicrovascularity bymeasurement, analysis and display of contrast agent uptake kinetics. J.Magn. Reson. Imaging. 7(3), 564–574.
167. Li KL, Henry RG, Wilmes LJ, Gibbs J, Zhu X, Lu Y, et al. (2007). Kinetic assessment of breast tumors using high spatial resolution signal enhancement ratio (SER) imaging.Magn. Reson.Med. 58(3), 572–581.
168. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, et al. (2007). AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn. Reson. Imaging. 25(3), 319–327.
169. Hylton N. (2006).Dynamic contrast-enhancedmagnetic resonance imaging as an imaging biomarker. J. Clin. Oncol. 24(20), 3293–3298.
170. Leach MO, Brindle KM, Evelhoch J., Griffiths JR, Horsman MR, Jackson A, et al. (2003). Assessment of antiangiogenic and antivascular therapeutics using MRI: Recommendations for appropriate methodology for clinical trials. Br. J. Radiol. 76 Spec No. 1, S87–S91.
171. Leach MO, Brindle KM, Evelhoch J., Griffiths JR, Horsman MR, Jackson A, et al. (2005). The assessment of antiangiogenic and antivascular therapies in earlystage clinical trials using magnetic resonance imaging: Issues and recommendations. Br. J. Cancer. 92(9), 1599–1610.
172. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. (2003). Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br. J. Cancer. 88(10), 1592–1597.
173. Roberts C, Issa B, Stone A, Jackson A, Waterton JC, & Parker GJ. (2006). Comparative study into the robustness of compartmentalmodeling and model-free analysis in DCE-MRI studies. J.Magn. Reson. Imaging. 23(4), 554–563.
174. Evelhoch JL. (1999). Key factors in the acquisition of contrast kinetic data for oncology. J.Magn. Reson. Imaging. 10(3), 254–259.
175. Padhani AR, &Husband JE. (2001).Dynamic contrast-enhancedMRI studies in oncology with an emphasis on quantification, validation and human studies. Clin. Radiol. 56(8), 607–620.
176. Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, et al. (2002). Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: Comparison of quantitative and semi-quantitative analysis. NMR Biomed. 15(2), 132–142.
177. Padhani AR, Hayes C, Landau S, & Leach MO. (2002). Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed. 15(2), 143– 153.
178. Ashton E, Raunig D, Ng C, Kelcz F, McShane T, & Evelhoch J. (2008). Scanrescan variability in perfusion assessment of tumors inMRI using both model and data-derived arterial input functions. J.Magn. Reson. Imaging. 28(3), 791– 796.
179. Galbraith SM, Rustin GJ, Lodge MA, Taylor NJ, Stirling JJ, Jameson M, et al. (2002). Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhancedmagnetic resonance imaging. J. Clin. Oncol. 20(18), 3826–3840.
180. Lankester KJ, Taylor NJ, Stirling JJ, Boxall J, D’Arcy JA, Leach MO, et al. (2005). Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumoursmeasured by dynamic MRI. Br. J. Cancer. 93(9), 979–985.
181. O’Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, et al. (2005). A phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points. Br. J. Cancer. 93(8), 876–883.
182. McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR, et al. (2005). Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone- 4-acetic acid, using in vivomagnetic resonance spectroscopy. Clin. Cancer Res. 11(10), 3705–3713.
183. McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, Kelland LR, et al. (2006). Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrastenhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 8(3), 199–206.
184. Checkley D, Tessier JJ, Kendrew J, Waterton JC, & Wedge SR. (2003). Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours. Br. J. Cancer. 89(10), 1889– 1895.
185. Marzola P, Degrassi A, Calderan L, Farace P, Crescimanno C, Nicolato E, et al. (2004). In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model. Clin. Cancer Res. 10(2), 739–750.
186. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, et al. (2005). Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin. Cancer Res. 11(16), 5827–5832.
187. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, et al. (2003). Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J. Clin. Oncol. 21(15), 2831–2842.
188. Evelhoch J., LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. (2004).Magnetic resonance imagingmeasurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin. Cancer Res. 10(11), 3650–3657.
189. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, et al. (2006). Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): Translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chemother. Pharmacol. 57(6), 761–771.
190. Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, et al. (2005). PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6melanoma tumours and inhibits their growth in vivo. NMR Biomed. 18(5), 308–321.
191. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, et al. (2003). Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J. Clin. Oncol. 21(21), 3955–3964.
192. Chen K, Cai W, Li ZB, Wang H, & Chen X. (2009). Quantitative PET imaging of VEGF receptor expression. Mol. Imaging Biol. 11(1), 15–22.
193. Levashova Z, Backer M, Backer JM, & Blankenberg FG. (2009). Imaging vascular endothelial growth factor (VEGF) receptors in turpentine-induced sterile thigh abscesses with radiolabeled single-chain VEGF. J. Nucl. Med. 50(12), 2058–2063.
194. Bading JR, & Shields AF. (2008). Imaging of cell proliferation: Status and prospects. J. Nucl.Med. 49(Suppl 2), 64S–80S.
195. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, Day MR, et al. (2001). Preoperative proton MR spectroscopic imaging of brain tumors: Correlation with histopathologic analysis of resection specimens. AJNR Am. J. Neuroradiol. 22(4), 604–612.
196. Nelson SJ, Graves E, Pirzkall A, Li X, Antiniw Chan A, Vigneron DB, et al. (2002). In vivo molecular imaging for planning radiation therapy of gliomas: An application of 1H MRSI. J.Magn. Reson. Imaging. 16(4), 464–476.
197. Vigneron D, Bollen A, McDermott M, Wald L, Day M, Moyher-Noworolski S, et al. (2001). Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn. Reson. Imaging. 19(1), 89– 101.
198. Kurhanewicz J, & Vigneron DB. (2008). Advances in MR spectroscopy of the prostate.Magn. Reson. Imaging Clin. N. Am. 16(4), 697–710
199. Scheenen TW, Klomp DW, Roll SA, Futterer JJ, Barentsz JO, & Heerschap A. (2004). Fast acquisition-weighted three-dimensional protonMR spectroscopic imaging of the human prostate.Magn. Reson.Med. 52(1), 80–88.
200. Jung JA, Coakley FV, Vigneron DB, Swanson MG, Qayyum A, Weinberg V, et al. (2004). Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system. Radiology. 233(3), 701–708.
201. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, et al. (2003). In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn. Reson.Med. 50(6), 1134–1143.
202. Baik HM, Su MY, Yu H, Mehta R, & Nalcioglu O. (2006). Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA. 19(2), 96– 104.
203. Kim JK, Park SH, Lee HM, Lee YH, Sung NK, Chung DS, et al. (2003). In vivo 1HMRS evaluation of malignant and benign breast diseases. Breast. 12(3), 179– 182.
204. Booth SJ, Pickles MD, & Turnbull LW. (2009). In vivomagnetic resonance spectroscopy of gynaecological tumours at 3.0 Tesla. BJOG. 116(2), 300–303.
205. Wang CK, Li CW, Hsieh TJ, Chien SH, Liu GC, & Tsai KB. (2004). Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: Initial results. Radiology. 232(2), 599–605.
206. Allen JR, Prost RW, Griffith OW, Erickson SJ, & Erickson BA. (2001). In vivo proton (H1)magnetic resonance spectroscopy for cervical carcinoma. Am. J. Clin. Oncol. 24(5), 522–529.
207. Baek HM, Chen JH, Nalcioglu O, & Su MY. (2008). Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann. Oncol. 19(5), 1022–1024.
208. Hsieh TJ, Li CW, Chuang HY, Liu GC, &Wang CK. (2008). Longitudinally monitoring chemotherapy effect of malignantmusculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: An initial experience. J. Comput. Assist. Tomogr. 32(6), 987–994.
209. Huang MQ, Nelson DS, Pickup S, Qiao H, Delikatny EJ, Poptani H, et al. (2007). In vivo monitoring response to chemotherapy of human diffuse large B-cell lymphoma xenografts in SCID mice by 1H and 31P MRS. Acad. Radiol. 14(12), 1531–1539.
210. Madhu B, Waterton JC, Griffiths JR, Ryan AJ, & Robinson SP. (2006). The response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy. Neoplasia. 8(7), 560–567.
211. Evelhoch J, Garwood M, Vigneron D, Knopp M, Sullivan D, Menkens A, et al. (2005). Expanding the use of magnetic resonance in the assessment of tumor response to therapy:Workshop report. Cancer Res. 65(16), 7041–7044.
212. Negendank W, Li CW, Padavic-Shaller K, Murphy-Boesch J, & Brown TR. (1996). Phospholipid metabolites in 1H-decoupled 31P MRS in vivo in human cancer: Implications for experimental models and clinical studies. Anticancer Res. 16(3B), 1539–1544.
213. Arias-Mendoza F, Zakian K, Schwartz A, Howe FA, Koutcher JA, Leach MO, et al. (2004).Methodological standardization for a multi-institutional in vivo trial of localized 31P MR spectroscopy in human cancer research. In vitro and normal volunteer studies. NMR Biomed. 17(6), 382–391.
214. Arias-Mendoza F, Payne GS, Zakian KL, Schwarz AJ, Stubbs M, Stoyanova R, et al. (2006). In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in amulti-institutional trial. NMR Biomed. 19(4), 504–512.
215. Dzik-Jurasz AS, Collins DJ, Leach MO, & Rowland IJ. (2000). Gallbladder localization of (19)F MRS catabolite signals in patients receiving bolus and protracted venous infusional 5-fluorouracil.Magn. Reson.Med. 44(4), 516–520.
216. Wolf W, Presant CA, & Waluch V. (2000). 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 41(1), 55–74.
217. Klomp DW, Van Laarhoven HW, Kentgens AP, & Heerschap A. (2003). Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver.Magn. Reson.Med. 50(2), 303–308.
218. Kamm YJ, Heerschap A, VanDen Bergh EJ, &Wagener DJ. (2004). 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil. Anticancer Drugs. 15(3), 229–233.
219. van Laarhoven HW, Punt CJ, Kamm YJ, & Heerschap A. (2005).Monitoring fluoropyrimidine metabolism in solid tumors with in vivo (19)F magnetic resonance spectroscopy. Crit. Rev. Oncol. Hematol. 56(3), 321–343.
220. Klomp D, van Laarhoven H, Scheenen T, Kamm Y, & Heerschap A. (2007). Quantitative 19FMRspectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver. NMR Biomed. 20(5), 485–492.
221. Reid DG, &Murphy PS. (2008). Fluorine magnetic resonance in vivo: A powerful tool in the study of drug distribution and metabolism. Drug Discov. Today. 13(11–12), 473–480.
222. Mankoff DA, Link JM, Linden HM, Sundararajan L, & Krohn KA. (2008). Tumor receptor imaging. J. Nucl.Med. 49(Suppl 2), 149S–63S.
223. Linden HM, Stekhova SA, Link JM, Gralow JR, Livingston RB, Ellis GK, et al. (2006). Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J. Clin. Oncol. 24(18), 2793–2799.
224. Faust A, Hermann S, Wagner S, Haufe G, Schober O, Schafers M, et al. (2009). Molecular imaging of apoptosis in vivo with scintigraphic and optical biomarkers – a status report. Anticancer AgentsMed. Chem. 9(9), 968–985.
225. Blankenberg FG. (2008). In vivo imaging of apoptosis. Cancer Biol. Ther. 7(10), 1525–1532.
226. Sanz J, & Fayad ZA. (2008). Imaging of atherosclerotic cardiovascular disease. Nature. 451(7181), 953–957.
227. Yuan C, Kerwin WS, Yarnykh VL, Cai J, Saam T, Chu B, et al. (2006). MRI of atherosclerosis in clinical trials. NMR Biomed. 19(6), 636–654.
228. Rudd JH, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. (2002). Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 105(23), 2708–2711.
229. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. (2006). In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasivemeasure of carotid plaque inflammation in patients. J. Am. Coll. Cardiol. 48(9), 1818–1824.
230. Takaya N, Cai J, Ferguson MS, Yarnykh VL, Chu B, Saam T, et al. (2006). Intraand interreader reproducibility of magnetic resonance imaging for quantifying the lipid-rich necrotic core is improved with gadolinium contrast enhancement. J.Magn. Reson. Imaging. 24(1), 203–210.
231. Saam T, Hatsukami TS, Yarnykh VL, Hayes CE, Underhill H, Chu B, et al. (2007). Reader and platform reproducibility for quantitative assessment of carotid atherosclerotic plaque using 1.5T Siemens, Philips, and General Electric scanners. J.Magn. Reson. Imaging. 26(2), 344–352.
232. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, et al. (2005). In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation. 112(22), 3437–3444.
233. Chu B, Zhao XQ, Saam T, Yarnykh VL, Kerwin WS, Flemming KD, et al. (2005). Feasibility of in vivo, multicontrast-weighted MR imaging of carotid atherosclerosis for multicenter studies. J. Magn. Reson. Imaging. 21(6), 809– 817.
234. Kerwin WS, O’Brien KD, Ferguson MS, Polissar N, Hatsukami TS, & Yuan C. (2006). Inflammation in carotid atherosclerotic plaque: A dynamic contrastenhanced MR imaging study. Radiology. 241(2), 459–468.
235. Rosen BD, Fernandes V, McClelland RL, Carr JJ, Detrano R, Bluemke DA, et al. (2009). Relationship between baseline coronary calcium score and demonstration of coronary artery stenoses during follow-up MESA (Multi-Ethnic Study of Atherosclerosis). JACC Cardiovasc. Imaging. 2(10), 1175–1183.
236. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. (2006). Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48(9), 1825–1831.
237. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, et al. (2001). Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution, noninvasive magnetic resonance imaging. Circulation. 104(3), 249–252.
238. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, et al. (2002). Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years’ follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation. 106(23), 2884–2887.
239. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF, et al. (2005). Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: A prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 46(1), 106–112.
240. Rudd JH, Machac J, & Fayad ZA. (2007). Simvastatin and plaque inflammation. J. Am. Coll. Cardiol. 49(19), 1991; author reply 1992.
241. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, Saam T, et al. (2008). Effect of rosuvastatin therapy on carotid plaquemorphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am. Heart J. 155(3), 584.e1–e8.
242. Saam T, Kerwin WS, Chu B, Cai J, Kampschulte A, Hatsukami TS, et al. (2005). Sample size calculation for clinical trials using magnetic resonance imaging for the quantitative assessment of carotid atherosclerosis. J. Cardiovasc.Magn. Reson. 7(5), 799–808.
243. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, et al. (2008). Atherosclerosis inflammation imaging with 18F-FDG PET: Carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl.Med. 49(6), 871–878.
244. Wong DF, Tauscher J, & Grunder G. (2009). The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology. 34(1), 187–203.
245. Takaya N, Yuan C, Chu B, Saam T, Underhill H, Cai J, et al. (2006). Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: A prospective assessment with MRI–initial results. Stroke. 37(3), 818–823.
246. Rominger A, Saam T, Wolpers S, Cyran CC, Schmidt M, Foerster S, et al. (2009). 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. J. Nucl. Med. 50(10), 1611–1620.